A Preliminary Study for Development of Clinical Practice Guidelines of Korean Medicine in Breast Cancer |
Lee, Kang-Wook
(Dept. of Internal Medicine, Cheonan Korean Medicine Hospital, Dae-Jeon University)
Yoo, Hwa-Seung (East-West Cancer Center, Dunsan Korean Medicine Hospital, Dae-Jeon University) Lee, Jin-Sun (Dept. of surgery, Chungnam National University Hospital, Chung-Nam National University) Lee, Nam-Hun (Dept. of Internal Medicine, Cheonan Korean Medicine Hospital, Dae-Jeon University) |
1 | Jung KH. Special Review: Personalized therapy for advanced breast cancer using molecular signatures. Korean Journal Med. 2009;77:26-34. |
2 | National Cancer Information Center. Breast Cancer(cited Mar 1, 2016). Available from:URL:http://www.cancer.go.kr/mbs/cancer/index.jsp. |
3 | Chen Z. Furenliangfangdaiquan. Seoul:Jungdam. 1993:71. |
4 | Chao Y. Chaoshizhubingyuan-houlun. Seoul:Daesung. 1992:296. |
5 | Zhang J. Jingyuequanshu. Shanghai :Shanghaikexuejishu. 1984:697. |
6 | Li X, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One. 2013;8(4):e60338. DOI |
7 | Korea Breast Cancer Society. Korea Breast Cancer Society Practice Recommendations of Breast Cancer 2008(cited Mar 1, 2016). Available from:URL:http://guideline.or.kr/guideline/guide/contents.php?number=27&F_sid=660. |
8 | National Comprehensive Cancer Network. NCCN Guidelines-Breast Cancer(cited Mar 1, 2016). Available from:URL:http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. |
9 | Lim HS. Guidelines for Diagnosis and Treatment of Malignant tumors in Chinese Medicine. Beijing:People’s Medical Publishing House. 2014:339-70. |
10 | EKAT 2010. Evidence Reports of Kampo Treatment 2010, 345 Randomized Controlled Trials(cited Mar 1, 2016). Available from:URL:http://www.jsom.or.jp/medical/ebm/ere/pdf/EKATE2010.pdf. |
11 | Fisher B, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400-18. DOI |
12 | Jones A, et al. Pilot Feasibility Study to Assess the Utility of PET Scanning in the Pre-Operative Evaluation of Internal Mammary Nodes in Breast Cancer Patients Presenting with Medial Hemisphere Tumors. Clin Positron Imaging. 1991;2:331. |
13 | Isasi CR, et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-12. DOI |
14 | Cook GJ, et al. Detection of bone metastases in breast cancer by 18 FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-9. DOI |
15 | Hata T, et al. Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg. 2004;198:190-7. DOI |
16 | Fisher B, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993-2000. DOI |
17 | Cooke T, et al. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol. 2001;12:S23-S28. DOI |
18 | American College of Radiology. Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. J Am Coll Surg. 2007;205:362-76. DOI |
19 | Cheng JC, et al. Diagnostic thoracic computed tomography in radiotherapy for locoregional recurrent breast carcinoma. Int J Radiat Oncol Biol Phys. 1998;41:607-13. DOI |
20 | Isasi CR, et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-12. DOI |
21 | Arriagada R, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996;14:1558-64. DOI |
22 | Cook GJ, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-9. DOI |
23 | Edge SB, et al. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. New York: Springer. 2010:143. |
24 | Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 1995;333:1444-55. DOI |
25 | Wood WC, et al. Dose and dose intensity of adjuvant chemotherapy for stageII, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-9. DOI |
26 | Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233-41. DOI |
27 | Veronesi U, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227-32. DOI |
28 | Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352:930-42. DOI |
29 | Wolmark N, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102. |
30 | Rastogi P, et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27. J Clin Oncol. 2008;26:778-85. DOI |
31 | Hellman S. Stopping metastases at their source. N Engl J Med. 2007;337:996-7. |
32 | Aman U. Buzdar. Preoperative chemotherapy treatment of breast cancer-a review. Cancer. 2007;110:2394-407. DOI |
33 | LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711-23. DOI |
34 | Overgaard M, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949-55. DOI |
35 | Klijn JG, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343-53. DOI |
36 | Ragaz J, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956-62. DOI |
37 | Ragaz J, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116-26. DOI |
38 | Overgaard M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet. 1999;353:1641-8. DOI |
39 | Danish Breast Cancer Cooperative Group. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82b and c randomized studies. J Clin Oncol. 2006;24:2268-75. DOI |
40 | Overgaard M, et al. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247-53. DOI |